Cybin Inc. (CYBN) stock surged +1.22%, trading at $8.28 on AMEX, up from the previous close of $8.18. The stock opened at $8.28, fluctuating between $8.14 and $8.38 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jan 02, 2026 | 8.27 | 8.38 | 8.14 | 8.28 | 713.6K |
| Dec 31, 2025 | 8.00 | 8.40 | 7.85 | 8.18 | 1.19M |
| Dec 30, 2025 | 9.00 | 9.12 | 8.41 | 8.57 | 1.69M |
| Dec 29, 2025 | 8.30 | 8.74 | 8.28 | 8.71 | 1.48M |
| Dec 26, 2025 | 8.17 | 8.40 | 8.00 | 8.34 | 1.02M |
| Dec 24, 2025 | 7.59 | 8.25 | 7.50 | 8.16 | 1.04M |
| Dec 23, 2025 | 7.11 | 7.92 | 7.02 | 7.85 | 1.7M |
| Dec 22, 2025 | 7.25 | 7.37 | 6.94 | 7.17 | 639.97K |
| Dec 19, 2025 | 6.80 | 7.21 | 6.77 | 7.18 | 1.24M |
| Dec 17, 2025 | 6.79 | 7.03 | 6.58 | 6.79 | 783.38K |
| Dec 16, 2025 | 6.62 | 6.81 | 6.53 | 6.66 | 421.66K |
| Dec 15, 2025 | 6.90 | 7.06 | 6.56 | 6.66 | 702.94K |
| Dec 12, 2025 | 6.35 | 6.84 | 6.35 | 6.68 | 878.05K |
| Dec 11, 2025 | 6.01 | 6.43 | 5.95 | 6.30 | 1.01M |
| Dec 10, 2025 | 5.79 | 6.01 | 5.70 | 5.97 | 801.55K |
| Dec 09, 2025 | 5.91 | 6.02 | 5.74 | 5.75 | 434K |
| Dec 08, 2025 | 6.05 | 6.06 | 5.61 | 5.91 | 702.98K |
| Dec 05, 2025 | 6.00 | 6.20 | 5.97 | 5.99 | 412.52K |
| Dec 04, 2025 | 5.70 | 6.00 | 5.64 | 5.95 | 630.98K |
| Dec 03, 2025 | 5.82 | 5.85 | 5.60 | 5.63 | 751.57K |
Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds. Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.
| Employees | 50 |
| Beta | 0.79 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | March |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep